SUNESIS PHARMACEUTICALS INC's ticker is SNSS and the CUSIP is 867328700. A total of 6 filers reported holding SUNESIS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $24,000 | -53.8% | 88,623 | -29.3% | 0.00% | – |
| Q1 2020 | $52,000 | +13.0% | 125,431 | -7.2% | 0.00% | – |
| Q4 2019 | $46,000 | -63.8% | 135,104 | -23.3% | 0.00% | – |
| Q3 2019 | $127,000 | -28.2% | 176,260 | -28.1% | 0.00% | – |
| Q2 2019 | $177,000 | +23.8% | 245,122 | +108.3% | 0.00% | – |
| Q1 2019 | $143,000 | +581.0% | 117,693 | +129.0% | 0.00% | – |
| Q4 2018 | $21,000 | -96.7% | 51,400 | -84.0% | 0.00% | – |
| Q3 2018 | $642,000 | +68.1% | 321,130 | +78.5% | 0.00% | – |
| Q2 2018 | $382,000 | -36.9% | 179,935 | -19.1% | 0.00% | – |
| Q1 2018 | $605,000 | +376.4% | 222,549 | +545.1% | 0.00% | – |
| Q4 2017 | $127,000 | +54.9% | 34,500 | -18.8% | 0.00% | – |
| Q3 2017 | $82,000 | -55.2% | 42,500 | -37.1% | 0.00% | – |
| Q2 2017 | $183,000 | +18.1% | 67,600 | +78.8% | 0.00% | – |
| Q1 2017 | $155,000 | -29.2% | 37,800 | -37.4% | 0.00% | – |
| Q4 2016 | $219,000 | -52.6% | 60,400 | -42.9% | 0.00% | – |
| Q3 2016 | $462,000 | – | 105,731 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 7,600,000 | $9,234,000 | 7.03% |
| Samsara BioCapital, LLC | 3,750,000 | $4,556,000 | 3.58% |
| CAXTON CORP | 277,245 | $337,000 | 0.31% |
| BVF INC/IL | 2,287,860 | $2,780,000 | 0.31% |
| Eventide Asset Management | 5,965,455 | $7,248,000 | 0.25% |
| Telemetry Investments, L.L.C. | 197,564 | $240,000 | 0.12% |
| NEA Management Company, LLC | 1,298,274 | $1,584,000 | 0.08% |
| RP Management, LLC | 129,517 | $158,000 | 0.08% |
| Palo Alto Investors LP | 1,162,473 | $1,412,000 | 0.06% |
| Fosun International Ltd | 725,000 | $863,000 | 0.06% |